Half-life

13 h

Tmax

11 h

Category

glp1

Liraglutide is a once-daily GLP-1 receptor agonist whose fatty-acid side chain enables albumin binding sufficient for a 13-hour half-life but not once-weekly dosing. It was the first GLP-1 RA approved for weight management (Saxenda) and remains widely used for type 2 diabetes (Victoza). Its shorter half-life means daily injection is required, which can be an advantage for patients who prefer tighter control over drug exposure or who experience side effects with longer-acting agents. Common injection sites are the abdomen, thigh, and upper arm. Tracking daily doses, nausea patterns, and weight trends helps patients and clinicians find the right dose schedule.

Mechanism

A GLP-1 receptor agonist with a fatty-acid acylation that promotes albumin binding and extends its half-life to allow once-daily dosing. Like other GLP-1 agonists it is associated with glucose-dependent insulin secretion, slowed gastric emptying, and reduced appetite.

Research summary

Approved for type 2 diabetes (LEAD program; cardiovascular outcomes in LEADER) and, at a higher dose, for chronic weight management (SCALE program). Marketed as Victoza for diabetes and Saxenda for weight management.

Reported side effects

Gastrointestinal effects (nausea, vomiting, diarrhea) are most commonly reported. Prescribing information includes warnings such as thyroid C-cell tumor risk in rodents and pancreatitis. This is not a complete safety profile.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

LEADER cardiovascular outcomes trial and SCALE weight-management trials · New England Journal of Medicine (2016)search PubMed for liraglutide LEADER / SCALE
Victoza / Saxenda prescribing information · FDA prescribing information (2014)available via DailyMed / accessdata.fda.gov

References

Liraglutide PK reviewDOI: 10.2165/00003088-200948010-00003

TrackPep — це трекер. Він зберігає те, що ви вносите, і ніколи не рекомендує та не розраховує кількість препарату.